BioMarin Report Results of Vosoritide in P-III OLE Study for the Treatment of Children with Achondroplasia at ENDO 2021
Shots:
- The ongoing P-III OLE study involves assessing Vosoritide (15 mcg/kg) vs PBO in 119 children with achondroplasia. The CHMP opinion is expected in Europe in June 2021
- The results demonstrated increased AGV- baseline mean AGV of 4.28 cm/year- sustained restoration of a major portion of the growing deficit and improved height z-score through the second year of treatment- Similar efficacy after one year of treatment- crossed over to treatment with baseline mean AGV of 3.99 cm/year- mean AGV was 5.65 cm/year
- Vosoritide has also received ODD from FDA and EMA for the treatment of children with achondroplasia. The NDA filing is under review from the FDA with a PDUFA date of August 20- 2021
Ref: PRNewswire | Image: BioMarin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com